# Pemetrexed Plus Gemcitabine in Renal Cell Cancer

> **NCT00491075** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00491075
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-12
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Closed early for poor accrual.
- **Last updated:** 2013-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00491075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00491075, "Pemetrexed Plus Gemcitabine in Renal Cell Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00491075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*